Ypsomed Holding AG
YPHDF
Other OTC467.34
USD
+37.34
- -
Ypsomed Holding AG
YPHDF
(Other OTC)
Recent
price
467.34
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ypsomed Holding AG is a Swiss-based holding company specializing in the development, manufacture, and sale of custom-made injection and infusion systems for the self-administration of liquid medication. The company primarily serves pharmaceutical and biotechnology companies, focusing on patients with chronic conditions across multiple therapeutic areas. Its core products include injection systems such as reusable and disposable pens, autoinjectors, on-body delivery systems, and related pen needles. These products support the treatment of diabetes, growth disorders, infertility, and other chronic diseases. Ypsomed also provides contract manufacturing and development services, tailored delivery systems, and digital health integration solutions. The company operates two main business segments: Ypsomed Delivery Systems, which encompasses the design and manufacturing of injection devices; and the recently divested Diabetes Care segment, which marketed insulin pumps, infusion sets, pen needles, and blood glucose monitoring systems. Ypsomed maintains production facilities in Switzerland and a growing distribution network across Europe and globally. Founded in 1984, Ypsomed is headquartered in Burgdorf, Switzerland. In the last two years, Ypsomed has undergone significant strategic changes, including the completion of the sale of its Diabetes Care business in 2025 to TecMed AG, marking a strategic transformation into a pure-play injection specialist focused on injection systems and contract development for pharmaceutical companies. Ypsomed announced a growth roadmap aiming for consolidated sales between CHF 0.9 and 1.1 billion and an EBIT range of CHF 280 to 340 million. The company has expanded its commercial autoinjector sales, seeing a 46.2% growth recently, and is in the process of establishing a new production facility in Holly Springs, North Carolina, announced in late 2025, to strengthen its presence in the U.S. market. Ypsomed also increased its workforce and completed the sale of its subsidiary Ypsotec AG as part of portfolio optimization. These moves reflect its ambition to capitalize on emerging drug delivery markets and solidify its role as a critical partner within the pharma value chain. Overall, Ypsomed operates within the healthcare medical instruments and supplies industry, catering primarily to pharmaceutical and biotech clients globally with a focus on innovation in self-medication injection technologies and partnerships. The company’s product portfolio is distinguished by technologically advanced pen injectors, autoinjectors, on-body systems, and precision pen needles featuring proprietary click-on technology for convenience and safety. Ypsomed Holding AG remains committed to improving patient quality of life through safe, reliable, and user-friendly drug delivery solutions while expanding its global footprint via targeted growth and operational efficiency initiatives. This captures Ypsomed's core business, geographic reach, product range, and recent strategic developments including divestments, facility expansion, and financial growth targets, reflecting its current market position and future outlook. The information is based on publicly available sources as of late 2025.
Ypsomed Holding AG (YPHDF) Q4 2026 Earnings Call Transcript